Optimal duration of adjuvant endocrine therapy: how to apply the newest data

BACKGROUND: The benefit of 5 years of adjuvant endocrine therapy for women with hormone receptor-positive (HR(+)) breast cancer (BC) is beyond discussion. Nevertheless, the risk of recurrence of luminal BC persists for 15 years or more after diagnosis. Consequently, approaches of extended adjuvant t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wimmer, Kerstin, Strobl, Stephanie, Bolliger, Michael, Devyatko, Yelena, Korkmaz, Belgin, Exner, Ruth, Fitzal, Florian, Gnant, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764154/
https://www.ncbi.nlm.nih.gov/pubmed/29344105
http://dx.doi.org/10.1177/1758834017732966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764154/
https://www.ncbi.nlm.nih.gov/pubmed/29344105
http://dx.doi.org/10.1177/1758834017732966

Ejemplares similares